Mohammadhajan, Elmie Marie R.

HRN: 28-88-96  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/23/2026
CO-AMOXICLAV 625MG (TAB)
04/23/2026
04/30/2026
PO
625mg
BID X 7 Days
UTI, S/p NSVD With RMLE
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  Urinary TractReproductive Tract    Compliance to guidelines: